BACKGROUND: There is controversy about whether central nervous system stimulant (CNS) medication is an effective method of treating acquired attention deficits in children with acquired brain injury (ABI).
OBJECTIVE: The primary objective was to determine the effectiveness of stimulants on attention, concentration and executive function in children with ABI.
METHODS: Randomised, double-blind, placebo-controlled, multi-centre n-of-1 trials of stimulants assessing effect on attention, concentration and executive function in 53 children and adolescents with ABI who were outpatients of three tertiary hospitals in Australia. Trials consisted of 3 two-week cycles, each cycle consisting of stimulant medication at doses titrated by physician (1 week) and placebo (1 week) in random order. The effect on parent and teacher Conners’ 3 and Behaviour Rating Inventory of Executive Function (BRIEF) was analysed using hierarchical Bayesian methods.
RESULTS: Overall, Teacher Conners’ Hyperactivity/Impulsivity and Teacher BRIEF Global Executive scales showed important improvement (T-score mean change 2.6; 95% credible interval (CI): 0.4, 4.9; posterior probability of mean change >0 : 0.99; T-score mean change 3.1; 95% CI: –0.1, 6.4; posterior probability of mean change >0 : 0.97). There were no important improvements in parent/guardian-reported primary outcomes. There was heterogeneity in response identified through individual results of the N-of-1 trials.
CONCLUSIONS: N-of-1 trials have a clear role in identifying those children/adolescents with ABI and secondary Attention Deficit Hyperactivity Disorder (ADHD) who have important improvements, or worsening on stimulants. The results can only be generalized to children/adolescents who have an apparent pre-trial clinical effect from stimulants.
BakkerK., & WaughM. C. (2000). Stimulant use in pediatric acquired brain injury: Evaluation of a protocol. Brain Impairment, 1, 29–36.
2.
BakkerK., & WaughM. C. (2008). Efficacy of stimulant medication in pediatric acquired brain injury. Final Report. http://www.maa.nsw.gov.au/default.aspx?MenuID=374 Accessed 16 August 2011, Motor Accidents Authority.
3.
BarkleyRAHyperactive children: A handbook for diagnosis and treatment. New York: Guildford Press; 1981.
4.
Brain Injury Association of Australia. http://www.braininjuryaustralia.org.au/. 2015. Accessed 9 Nov 2015.
5.
BrownR. T., AmlerR. W., FreemanW. S., PerrinJ. M., SteinM. T., FeldmanH. M., PierceK., WolraichM. L., & American Academy of Pediatrics Committee on Quality Improvement, American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity, Disorder (2005). Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics, 115(6), e749–e757.
6.
BrownG. L., HuntR. D., EbertM. H., BunneyW. E.Jr., & KopinI. J. (1979). Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. Psychopharmacology (Berl), 62(2), 133–140.
7.
CatroppaC., AndersonV. A., MorseS. A., HaritouF., & RosenfeldJ. V. (2006). Children’s attentional skills 5 years post-TBI. J Pediatr Psychol, 32(3), 354–369. Epub
8.
ConnersC. K., SitareniosG., ParkerJ. D. A., & EpsteinJ. N. (1998). Revision and restandardisation of the Conners Teacher Rating Scale (CTRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol, 26, 279–291.
9.
ConnersC. K. (2008). Connors Third Edition. Multi-Health Systems, Toronto, Ontario.
10.
GerringJ. P., BradyK. D., ChenA., VasaR., GradosM., Bandeen-RocheK. J., BryanR. N., & DencklaM. B. (1998). Premorbid prevalence of ADHD and development of secondary ADHD after closed head injury. J Am Acad Child Adolesc Psychiatry, 37(6), 647–654.
11.
GioiaG. A., IsquithP. K., GuyS. C., et al. (2000). Behavior rating inventory of executive function. Child Neuropsychol, 6(3), 235–238.
12.
GoyetteC., ConnersC., & UlrichR. (1978). Normative data on normative data on revised conners parent and teacher rating scales. J Abn Child Psychology, 6(2), 221–236.
13.
GuiltierC. T., & EvansR. W. (1988). Stimulant treatment for the neurobehavioral squeal of traumatic brain injury. Brain Injury, 2, 273–290.
14.
HarveyD., MorrallM., NeillyE., & Murdoch-EatonE. (2012). Should stimulants be administered to manage difficulties with attention, hyperactivity and impulsivity following paediatric acquired brain injury?Arch Dis Child, 97, 755–758. doi: 10.1136/archdischild-2012-302250
15.
NiklesJ., McKinlayL., MitchellG., CarmontS.-A., SeniorH., WaughM.-C., EppsmA., SchluterP., & LloydO. (2014). Aggregated n-of-1 trials of CNS stimulants versus placebo for paediatric traumatic brain injury - a pilot study. Trials, 15, 54.
16.
JinC., & SchacharR. (2004). Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: A critical appraisal of treatment studies. CNS Spectrums, 9, 217–226.
17.
LevinH., HantanG., MaxJ., LiX., SwankP., Ewing-CobsL., DennisM., MenifeeD. S., & StincharR. (2007). Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children. J Dev Behave Pediatric, 28(2), 108–118.
18.
MahalickD. M., CarmelP. W., GreenbergJ. P., et al. (1998). Psychopharmacologic treatment of acquired attention disorders in children with brain injury. Pediatric Neurosurgery, 29, 121–126.
19.
MaxJ. E., SchacharR. J., LevinH. S., Ewing-CobbsL., ChapmanS. B., DennisM., SaundersA., & LandisJ. (2005). Predictors of attention-deficit/hyperactivity disorder within 6 months after pediatric traumatic brain injury. J Am Acad Child Adolesc Psychiatry, 44(10), 1032–1040.
20.
MendozaT. R., LaudicoA. V., WangX. S., GuoH., MatsudaM. L., YosuicoV. D., FraganteE. P., & CleelandC. S. (2010). Assessment of fatigue in cancer patients and community dwellers: Validation study of the Filipino version of the BRIEF fatigue inventory. Oncology, 79(1-2), 112–117. doi: 10.1159/000320607. Epub 2010 Nov, 22.
21.
MendozaT. R., WangX. S., CleelandC. S., MorrisseyM., JohnsonB. A., WendtJ. K., et al. (1999). The rapid assessment of fatigue severity in cancer patients: Use of the BRIEF fatigue inventory. Cancer, 85, 1186–1196.
22.
Novartis. Ritalin hydrochloride product information sheet. East Hanover, New Jersey: Novartis, 2010.
23.
OrnsteinT. J., SagarS., SchacharR. J., Ewing-CobbsL., ChapmanS. B., DennisM., SaundersA. E., YangT. T., LevinH. S., & MaxJ. E. (2014). Neuropsychological performance of youth with secondary attention-deficit/hyperactivity disorder 6- and 12-months after traumatic brain injury. J Int Neuropsychol Soc, 20(10), 971–981.
24.
SchluterP. J., & WareR. S. (2005). Single patient (n-of-1) trials with binary treatment preference. Statistics in Medicine, 24, 26252636.
25.
SeniorH., McKinlayL., NiklesJ., SchluterP., CarmontS., WaughM., EppsA., LloydO., & MitchellG. (2013). Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: A rationale and protocol for single patient (N-of-1) multiple cross-over trials. BMC Pediatrics, 13, 89.
26.
TeasdaleG. (1974). Assessment of coma and impaired consciousness. A practical scale. Lancet, 2, 81–84.
27.
ThummelK. E., & LinY. S. (2014). Sources of interindividual variability. Methods Mol Biol, 1113, 363–415. doi: 10.1007/978-1-62703-758-7_17
28.
VanceA., WintherJ., & RennieK. (2012). Management of attention-deficit/hyperactivity disorder: The importance of psychosocial and medication treatments. J Paediatr Child Health, 48(2), E33–E37.
29.
YeatesK. O., ArmstrongK., JanuszJ., et al. (2005). Long-term attention problems in children with traumatic brain injury. J Am Acad Child Adolesc Psychiatry, 44(6), 574–584.
30.
ZuckerD. R., SchmidC. H., McIntoshM. W., et al. (1997). Combining single patient [N-of-1] trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol, 50, 401410.
